Coherence

Based in California, Coherence Neuro specializes in advanced therapeutic neurotechnology, focusing on innovative solutions for cancer management through its proprietary brain-computer interface, SOMA. Coherence Neuro, founded in 2022 in San Francisco, US, develops neurotechnological solutions aimed at managing cancer treatment effectively. In October 2026, Coherence raised USD 45 million in seed funding co-led by Founders Fund and Openai Startup Fund Management, with participation from Lux Capital, 8VC, Timeless, Olive Capital, Ahren Innovation Capital, Topology, Artesian, XEIA Venture Partners, Xtal and Divergent Capital. Coherence specializes in advanced therapeutic neurotechnology, primarily through its flagship product, SOMA, a therapeutic brain-computer interface designed to monitor and manage cancer treatment continuously.

SOMA operates by administering custom bioelectronic stimulation tailored to the unique physiological characteristics of each patient, aiming to keep cancer in check on a 24/7 basis. The system includes a discreet wireless implant, a minimalist wearable device, and a companion app that delivers real-time insights and symptom tracking. This innovative approach addresses the critical need for personalized, targeted cancer therapies, directly impacting patients’ quality of life by allowing them to manage their treatment discreetly and effectively. Coherence's products are particularly targeted toward oncology patients and healthcare providers seeking to integrate cutting-edge neurotechnological solutions into their treatment plans, with potential markets spanning North America, Europe, and parts of Asia.

Coherence generates revenue through the commercialization of its SOMA system, which is structured around direct-to-consumer sales and partnerships with healthcare providers. The company’s business model includes subscription services for ongoing software updates and patient support, ensuring that users receive the latest advancements and personalized care. Revenue transactions involve the sale of the SOMA implant, wearable device, and app, with potential bundled pricing options that encourage comprehensive adoption of the entire system. The firm targets both individual patients and institutional healthcare settings, positioning its services as critical components in modern cancer management strategies.

Specific pricing structures for these innovative products reflect their unique therapeutic value and the personalization of treatment they offer. The company plans to utilize the October 2026 funding to advance its first chronic human glioblastoma trial, FDA breakthrough device designation efforts, preclinical pancreatic and other cancer research, device development, and team expansion.